Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Francis D, Sen S. Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. European Heart Journal 2018, 39: 3620-3620. PMID: 30137277, DOI: 10.1093/eurheartj/ehy498.Peer-Reviewed Original ResearchPatent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, Malik I, Davies J, Mayet J, Francis D, Sen S. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. European Heart Journal 2018, 39: 1638-1649. PMID: 29590333, PMCID: PMC5946888, DOI: 10.1093/eurheartj/ehy121.Peer-Reviewed Original ResearchMeSH KeywordsForamen Ovale, PatentHumansRandomized Controlled Trials as TopicRecurrenceSeptal Occluder DeviceStrokeTreatment OutcomeConceptsMedical therapyCryptogenic strokeDevice closurePFO closureAtrial fibrillationRecurrent strokeLarge shuntPatent foramenNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointAtrial septal aneurysmPrevention of strokeSignificant reductionEfficacy endpointFurther strokeSafety endpointTreat basisSeptal aneurysmSmall shuntPatientsTherapyStroke